OPTIGENEX INC.
AC-11, a patented natural compound that stimulates endogenous DNA repair mechanisms
- Sector
- Biotech
- Headquarters
- HOBOKEN, NJ
- Latest Form D
- $630K, Nov 2017
- Total capital
- $630K
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $630K
- 1 Form D · last Nov 2017
- 107 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 2 pending · first 2018
- Rank in peer group#397 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$630K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#397 · top 27%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Vincent GiampapaResearcherDirectorLinked by 1 patent
- Dan ZwirenExecutive OfficerNamed in SEC Form D filings
- Jenifer GraceDirectorNamed in SEC Form D filings
- Joe WoodDirectorNamed in SEC Form D filings
- Steven MarcusExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 4- GrantedMethod Of Enhancing Cognition In Individuals With At Least Normal CognitionUSPTOUS 11,883,457
- GrantedIncreasing Telomere Length In A CellUSPTOUS 10,098,922
- PendingMethod Of Enhancing Cognition In Individuals With At Least Normal CognitionUSPTOApplication PCTUS2023032041
Show all 4 patent records
- Method Of Enhancing Cognition In Individuals With At Least Normal CognitionJan 30, 2024 · US 11,883,457Granted
- Increasing Telomere Length In A CellOct 16, 2018 · US 10,098,922Granted
- Method Of Enhancing Cognition In Individuals With At Least Normal CognitionApplication PCTUS2023032041Pending
- Increasing Telomere Length In A CellApplication PCTUS2018062201Pending
Related companies, and why
- Paradise Genomics, Inc.Similar federal contract value in Biotech · null in contracts
- ENGEN BIO, LLCSimilar federal contract value in Biotech · null in contracts
- Embold Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Mydecine Innovations Group Inc.Similar federal contract value in Biotech · null in contracts
- Parnell Pharmaceuticals Holdings LtdSimilar federal contract value in Biotech · null in contracts
- Intervene Immune, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .